Table 6 Clinical research on radiotherapy combined with single-drug/double-drug chemotherapy for the treatment of esophageal squamous cell carcinoma in the EPs
From: Radiotherapy with S-1 for the treatment of esophageal squamous cell carcinoma 75 years or older
Study | Sample size | Study type | Age(year) | stage | Treatment | Completion rate (%) | mOS(months) | 2-year OS rate (%) | AEs (grade ≥ 3) (%) |
|---|---|---|---|---|---|---|---|---|---|
Liu (2022) [9] | 34 | prospective | 72–80 | II-III | RT vs. CCRT: IF-IMRT (50–60 Gy/25–30 F) + S-1 | 100 | 23.0 vs. 27.0 | 47.1 vs. 58.8 | 1.4 vs. 5.8 |
Wang (2017) [18] | 56 | retrospective | 70–87 | II-IV | CCRT: RT (54.0 Gy/27–30 F) + S-1 + cisplatin | 67.9 | 18.2 | 45.6 | 55.4 |
S E Anderson (2007) [16] | 25 | retrospective | 66–88 | II-III | CCRT: RT (50.4 Gy/28F) + 5-FU + mitomycin | 88.0 | 35.0 | 64.0 | 36.0 |
Xing (2014) [20] | 75 | retrospective | 65–74 | I-IV | CCRT vs. SCRT: RT (54.0–60 Gy/30–33 F) + capecitabine + cisplatin | 68.9 vs. 96.7 | 15.7 vs. 11.6 | 60.2 vs. 45.3 | 45.2 vs. 17.2 |
Huang (2019) [21] | 271 | retrospective | 65–89 | I-IV | RT vs. RT (40–74 Gy) + docetaxel/ platinum/5-FU vs. RT (40–74 Gy) + platinum + 5-FU/paclitaxel/docetaxel | NA | 15.6 vs. 28.8 vs.27.8 | 39.0 vs. 59.0 vs.57.0 | 8.5 vs. 26.3 vs.45.8 |
Hulshof (2021) [22] | 260 | prospective | 34–90 | I-IVb | RT (50.4 Gy) + PC vs. RT (61.6 Gy) + PC | 93.1 vs. 87.7 | 25.7 vs. 24.6 | 50.8 vs. 40.8 | 55.0 vs. 63.6 |
Jia (2024)[23] | 246 | prospective | 61–71 | II-IV | RT (50 Gy/25F) + capecitabine vs. RT + XELOX vs. RT + PF | 100 | 40.9 vs. 41.9 vs.35.4 | 75.0 vs. 66.7 vs. 70.9 | 28.8% vs.36.5%, vs.45.7% |